Literature DB >> 12511366

Misleading statistical calculations in far-advanced glaucomatous visual field loss.

Eytan Z Blumenthal1, Ruthy Sapir-Pichhadze.   

Abstract

OBJECTIVE: In this study, the capability of statistical analysis indices to characterize static automated visual fields (VFs) accurately in cases of far-advanced glaucoma was assessed.
DESIGN: Retrospective observational case series. PARTICIPANTS: Sixteen eyes of 15 patients with end-stage glaucoma and evidence of collapse of VF statistical analysis indices were included in the study.
METHODS: End-stage glaucoma was defined as vertical cup-to-disc ratio of 0.9 or more, mean deviation less than -24 dB and with only a central or temporal island remaining in the VF gray scale. Collapse of statistical indices was defined as any of the following: pattern deviation probability plot without a single VF location showing P < 0.5%; corrected pattern standard deviation (CPSD) and pattern standard deviation (PSD) probability less than 5% or within normal limits (WNL); short-term fluctuation (SF) probability WNL; glaucoma hemifield test (GHT) not outside normal limits (ONL); or presence of a low patient reliability comment triggered by 40% or more false-negative (FN) responses. MAIN OUTCOME MEASURES: Visual field statistical indices.
RESULTS: Of the 16 VFs showing misleading statistical calculations, 9 of 16 eyes had a normal pattern deviation probability plot. The PSD, SF, and CPSD parameters were normal or barely outside the normal range in 4 of 16, 10 of 16, and 5 of 16 eyes, respectively. The GHT was ONL in 7 of 13 eyes, borderline with generalized reduction of sensitivity (GRS) in three eyes, and only GRS in two additional eyes. Low patient reliability was triggered because of an FN score of 40% or more in 10 of 16 eyes.
CONCLUSIONS: Statistical indices are crucial for the interpretation of automated static VFs. However, in end-stage glaucomatous VF loss, both summary statistical indices and reliability indices may not detect abnormality, thus misleading the casual observer.

Entities:  

Mesh:

Year:  2003        PMID: 12511366     DOI: 10.1016/s0161-6420(02)01297-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

1.  Effect of disease severity on the performance of Cirrus spectral-domain OCT for glaucoma diagnosis.

Authors:  Mauro T Leite; Linda M Zangwill; Robert N Weinreb; Harsha L Rao; Luciana M Alencar; Pamela A Sample; Felipe A Medeiros
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-24       Impact factor: 4.799

2.  Variability of visual field measurements is correlated with the gradient of visual sensitivity.

Authors:  Harry J Wyatt; Mitchell W Dul; William H Swanson
Journal:  Vision Res       Date:  2007-02-23       Impact factor: 1.886

3.  A novel strategy for the estimation of the general height of the visual field in patients with glaucoma.

Authors:  Iván Marín-Franch; William H Swanson; Victor E Malinovsky
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-18       Impact factor: 3.117

4.  Clinical Correlates of Computationally Derived Visual Field Defect Archetypes in Patients from a Glaucoma Clinic.

Authors:  Sophie Cai; Tobias Elze; Peter J Bex; Janey L Wiggs; Louis R Pasquale; Lucy Q Shen
Journal:  Curr Eye Res       Date:  2016-08-05       Impact factor: 2.424

5.  OCT Circle Scans Can Be Used to Study Many Eyes with Advanced Glaucoma.

Authors:  Seung H Lee; Devon B Joiner; Emmanouil Tsamis; Rashmi Rajshekhar; Eleanor Kim; C Gustavo De Moraes; Robert Ritch; Donald C Hood
Journal:  Ophthalmol Glaucoma       Date:  2019-02-12

6.  Performance of glaucoma progression analysis software in a glaucoma population.

Authors:  Francisco Arnalich-Montiel; Pilar Casas-Llera; Francisco J Muñoz-Negrete; Gema Rebolleda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-04       Impact factor: 3.117

Review 7.  Macular imaging with optical coherence tomography in glaucoma.

Authors:  Vahid Mohammadzadeh; Nima Fatehi; Adeleh Yarmohammadi; Ji Woong Lee; Farideh Sharifipour; Ramin Daneshvar; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Surv Ophthalmol       Date:  2020-03-19       Impact factor: 6.048

8.  CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States.

Authors:  Louis R Pasquale; Stephanie J Loomis; Jae H Kang; Brian L Yaspan; Wael Abdrabou; Donald L Budenz; Teresa C Chen; Elizabeth Delbono; David S Friedman; Douglas Gaasterland; Terry Gaasterland; Cynthia L Grosskreutz; Richard K Lee; Paul R Lichter; Yutao Liu; Catherine A McCarty; Sayoko E Moroi; Lana M Olson; Tony Realini; Douglas J Rhee; Joel S Schuman; Kuldev Singh; Douglas Vollrath; Gadi Wollstein; Donald J Zack; R Rand Allingham; Margaret A Pericak-Vance; Robert N Weinreb; Kang Zhang; Michael A Hauser; Julia E Richards; Jonathan L Haines; Janey L Wiggs
Journal:  Am J Ophthalmol       Date:  2012-10-27       Impact factor: 5.258

9.  Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma.

Authors:  Alessandro Lambiase; Luigi Aloe; Marco Centofanti; Vincenzo Parisi; Sonia Nair Báo; Flavio Mantelli; Valieria Colafrancesco; Gian Luca Manni; Massimo Gilberto Bucci; Stefano Bonini; Rita Levi-Montalcini
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-11       Impact factor: 11.205

10.  Validation of the Glaucoma Quality of Life-15 Questionnaire in Serbian language.

Authors:  Ivan Sencanic; Tatjana Gazibara; Jelena Dotlic; Miroslav Stamenkovic; Vesna Jaksic; Marija Bozic; Anita Grgurevic
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.